Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Research output: Contribution to journalReview article

13 Scopus citations


This review discusses completed phase II randomized clinical trials with high-quality published results for compounds that demonstrate effects on nonalcoholic steatohepatitis histology (obeticholic acid, elafibranor, and liraglutide). The authors also review the available preliminary data on cenicriviroc and selonsertib, with or without simtuzumab's phase II studies. Finally, the authors briefly discuss compounds that have been tested but did not achieve the primary end point of histologic improvement and appeared in high-quality published articles (cysteamine bitartrate and long-chain polyunsaturated fatty acids).

Original languageEnglish (US)
Pages (from-to)189-199
Number of pages11
JournalClinics in Liver Disease
Issue number1
StatePublished - Feb 2018


  • Cenicriviroc
  • Elafibranor
  • Liraglutide
  • NASH
  • Obeticholic acid
  • Selonsertib

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis'. Together they form a unique fingerprint.

  • Cite this